NMN Fight, New Frontiers: Niagen's First Quarter Has a Lot in the Air

Q1 in a snapshot

Niagen Bioscience (NAGE) delivered a solid first quarter: revenue of $31.5M, up 5% year-over-year excluding the divested reference standard business, and net income of $6.3M, up from $5.1M last year. The balance sheet remains fortress-like with $66.5M in cash and no debt. Yet the market has been punishing the stock — down 29% over the last 90 days and still 83% below its February 2021 peak. The most likely culprits are not operational: they are the twin overhangs of the FDA's reversal on NMN product legality and the company's own lawsuit against the agency.

The core business is actually accelerating. NR chloride (patented as NIAGEN) now has a published USP monograph, a rarity for a supplement. E-commerce grew 14% year-over-year, and the direct-to-consumer website grew twice as fast as Amazon. “We think NMN is a good ingredient, and it does effectively elevate NAD. It does not do it nearly as well as NIAGEN.” — Rob Fried, Chief Executive Officer · 2026-05-06 That is the crux of the competitive threat the company is fighting.

The NMN cloud

Since the FDA reversed its drug-preclusion ruling in September, the supplement market has seen a flood of NMN sellers. “I cannot give you a precise number, but we see an increase in bidding costs for keyword searches on Amazon and elsewhere, and we see more difficulty getting new-to-brand customers.” — Rob Fried, Chief Executive Officer · 2026-05-06 Management estimates there are now more than 300 NMN SKUs on Amazon, up from zero in September. The company is suing the FDA, arguing the reversal was arbitrary — and it is confident the decision will be overturned again.

We sued the FDA because we think that their ruling reversing the drug preclusion decision was incorrect. The FDA replied to that lawsuit recently, last week, and we are awaiting hearings on that reply and then the judge’s decision.

This legal overhang is a genuine overhang on the stock. The company says it expects a decision within a year. In the meantime, every dollar of marketing spend is being fought over by cheaper NMN rivals. The prior call had already signaled the risk, as “We do see increased competition. NMN did get reversed by the FDA, their ruling. We think there's a good chance they're going to re-reverse that decision in the coming year.” — Robert Fried, Chief Executive Officer · 2026-03-04 That re-reversal has not happened, and the uncertainty is weighing on sentiment.

New growth levers

Beyond the legal battle, Niagen is actively expanding its product portfolio. The most significant is the launch of the Niagen Plus at-home injection kit, which began shipping just days before the call. “It has taken us many years. We are very, very excited to be there. It is only four or five days, but it has been, I would say, outstanding those first four or five days in terms of traffic and conversions.” — Rob Fried, Chief Executive Officer · 2026-05-06 The kit is initially available only through select telehealth channels, with California still awaiting pharmacy licensing — but the early traction has been encouraging.

The company is also scaling NanoCloud, its first topical skincare product, which pilot-launched in March and is nearly sold out. A wide rollout is planned for October. Additionally, management confirmed it is in talks with two major skincare brands to supply NIAGEN as an ingredient, broadening the addressable market beyond supplements. The compounding pharmacy network is being expanded to include Olympia, which should help bring down clinic pricing and accelerate the adoption of Niagen IV/injectable treatments.

Financially, the company is maintaining discipline. Gross margin held at 63.5% (up 10 bps), and operating margin improved to 21.4%. The one blemish is cash flow: the company reported negative operating cash flow of $1.2M, driven by inventory buildup (a planned purchase from supplier W.R. Grace) and an Amazon policy change that withholds sales proceeds for seven days. The CFO expects inventory levels to decline through the year.

Perhaps the most telling metric is the spike in receivables: the ratio rose from 23% to 42% year-over-year. That is a timing issue, not a credit issue, but it explains the working capital drag.

Investors are clearly focused on the NMN legal case and the competitive onslaught, but the company’s product pipeline and e-commerce momentum suggest the fundamental story remains intact. If the FDA ruling is reversed again, the headwind could become a tailwind. If not, Niagen will need to rely on its science, brand, and new verticals to keep growing.